Melbourne, Australia
Nutromics, founded in 2017 and headquartered in Australia, is carving a niche in the intersection of Biotechnology, Health Care, and Medical Devices sectors. With its pioneering "lab-on-a-patch®" technology, Nutromics aims to transform diagnostic monitoring through a wearable device that provides continuous, real-time molecular insights, shifting away from traditional diagnostics that offer only delayed snapshots.
The platform leverages AI-designed, DNA-based biosensors, known as aptamers, to track multiple molecular targets simultaneously. This innovative approach empowers healthcare professionals with immediate data, leading to quicker decisions, improved treatment efficacy, and superior patient outcomes.
The company's initial focus is on monitoring the crucial antibiotic vancomycin, with further developments underway addressing sepsis, cardiology, and triage applications.
Nutromics recently completed a $7.50M Series A round of investment in September 2025, reflecting investor confidence in its potential to significantly impact healthcare diagnostics.
